Aphakia
Conditions
Keywords
Cataract, aphakia, intraocular lens, IOL, Optical correction of aphakia
Brief summary
The purpose of this study is to assess the safety and efficacy of the HMY Model YA-60BB Intraocular Lens (IOL) when implanted in the posterior chamber of the human eye for the optical correction of aphakia following cataract extraction.
Detailed description
A prospective, single-phase, non-randomized, open-label study to include patients with operable cataract of the human crystalline lens who have a potential post-operative best corrected visual acuity of 20/40 or better and no pre-existing progressive sight-threatening ocular disorders. Patients who are eligible per inclusion / exclusion criteria will undergo phacoemulsification cataract extraction and then implantation of the Hoya HMY Model YA-60BB posterior chamber intraocular lens. Each patient will be followed-up at specific time intervals to assess safety and effectiveness, for up to 36 months.
Interventions
DEVICEHMY Model YA-60BB IOL
Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
Sponsors
Hoya Surgical Optics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Adult patients with cataract who are eligible for phacoemulsification cataract extraction of the lens through an incision of approximately 4 mm, and primary implantation of a posterior chamber intraocular lens. 2. Patients must have no pre-existing ocular conditions that preclude the ability of the treated eye to achieve BCVA of 20/40 or better after IOL implantation. 3. Patients must be at least 21 years of age. 4. Patients must sign a written informed consent form. 5. Patients must be able and willing to return for scheduled follow-up examinations after surgery throughout the 36 month study.
Exclusion criteria
1. Patients with a history of/or clinical signs of any of the following sight-threatening conditions: 1. Previous Retinal Detachment or retinal pathology in operative eye, only 2. Macular Degeneration in either eye 3. Macular Edema in either eye 4. Persistent Iritis/Uveitis in operative eye, only 2. Uncontrolled Glaucoma or under current treatment for glaucoma in either eye 3. Significant Corneal Disease in operative eye, only 4. Proliferative Diabetic Retinopathy in either eye 5. Patients who have had previous ocular surgery, of any kind, within the last 6 months or patients who have had previous ocular surgery at any time and who do not have potential BCVA after cataract extraction/IOL implantation of 20/40 or better 6. Patients who have best corrected vision worse than 20/200 in the fellow eye. 7. Patients with serious (i.e., life threatening) non-ophthalmic disease which may preclude study completion. 8. Patients who have undergone previous cataract extraction and intraocular lens implantation. 9. Patients unwilling or unable to sign the IRB-approved informed consent document for the study or who cannot or will not complete the study's examination schedule. 10. Patients who are currently enrolled in another clinical trial, or who exited a clinical trial within the last 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best Corrected Visual Acuity | 12 months postoperative |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events/complications | 12 months postoperative |
Countries
United States
Outcome results
None listed